Vaxart Adjourns Annual Meeting for Reverse Stock Split

Vaxart ( (VXRT) ) has shared an update.

On June 2, 2025, Vaxart announced the adjournment of its 2025 annual meeting of stockholders to June 13, 2025, due to insufficient votes for a proposal to amend the company’s Restated Certificate of Incorporation for a reverse stock split. The company aims to provide additional time for stockholders to vote and solicit more support for the proposal, which is crucial for maintaining its Nasdaq listing. Leading proxy advisory firms ISS and Glass Lewis have endorsed the proposal, and Vaxart has engaged in discussions with major stockholders to address concerns, resulting in increased support.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall stock score reflects a company with strong revenue growth and significant clinical trial progress, bolstered by supportive corporate events. However, persistent profitability issues, cash flow challenges, and valuation concerns weigh on the score. The mixed sentiment from the earnings call and the high volatility associated with the stock further moderate the overall assessment.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company specializing in the development of oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, reducing the risk of needle-stick injuries. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV), marking its first foray into immune-oncology.

Average Trading Volume: 1,837,369

Technical Sentiment Signal: Sell

Current Market Cap: $98.88M

Learn more about VXRT stock on TipRanks’ Stock Analysis page.